Post-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey

Market: Pharma & Healthcare

Global, 9 pages report, published by Informa

Report ThumbnailJanuary-2017
We conducted a 5-question survey of 51 United States and 47 European (from France, Germany, Italy, Spain and United Kingdom) neurologists who currently treat patients in all stages of Alzheimer’s disease and who followed data presented at Clinical Trials on Alzheimer’s Disease (CTAD) 2016 to gauge their views on the pipeline anti-amyloid beta monoclonal antibodies solanezumab (LLY) and aducanumab (BIIB) and projected use of these potentially disease-modifying drugs if FDA-approved.



Read More
  • Survey
Read More

Please select a license type


Related Products

InformaPost-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 SurveyProduct ThumbnailPost-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey, Industry ReportProduct #: 770010
Global Markets Direct
GBI Research
PayPal Acceptance Mark
SSL Certificate
Copyright © 2021 Global Market Analyst. All Rights Reserved